
Medtronic plc (NYSE: MDT), the Irish-domiciled medical-device maker, will release second-quarter fiscal 2027 results (the quarter ended October 30, 2026) on Tuesday, November 24, 2026, before the U.S. market opens. The company says the news release comes at 5:45 a.m. Central Time (11:45 UTC, 13:45 in Bucharest) and the video webcast at 6:30 a.m. Central (12:30 UTC, 14:30 in Bucharest). The print is the first without the extra week that lifted Q1, so it is the first clean read on growth. Below: the recent quarters, each against the same quarter a year earlier, what the FY2027 guidance implies for the rest of the year, analyst expectations, the dividend, and what to watch.
The recent quarters, each against the same quarter a year earlier
| Metric (change vs same quarter a year earlier) | Q2 FY2026 (the base for Q2 FY2027) | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|
| Revenue (reported) | $8,961 million vs $8,403 million, +6.6% | $9,017 million vs $8,292 million, +8.7% | $9,807 million vs $8,927 million, +9.9% | $9,756 million vs $8,578 million, +13.7% |
| Revenue (organic, company) | +5.5% | +6.0% | +6.6% | +13.7% |
| Non-GAAP diluted EPS | $1.36 vs $1.26, +7.9% | $1.36 vs $1.39, -2.2% | $1.55 vs $1.62, -4.3% | $1.45 vs $1.26, +15.1% |
| GAAP diluted EPS | $1.07 vs $0.99 | $0.89 vs $1.01 | $0.96 vs $0.82 | $1.14 vs $0.81 |
| Items the company flags | Quarter ended October 24, 2025 | Quarter ended January 23, 2026 | Quarter ended April 24, 2026; currency added about $308 million to reported revenue (9.9% reported against 6.6% organic) | Quarter ended July 31, 2026, 14 weeks against 13; the extra week added about $570 million to organic growth (company estimate) |
Sources: Medtronic results releases of November 18, 2025, February 17, 2026, June 3, 2026 and September 1, 2026 (the year-earlier Q1 base comes from the September release). Percentage changes for reported revenue and EPS are my calculation from the figures reported and may differ from the company’s own rounding by 0.1 point; organic growth is the company’s figure. Q2 FY2026 is the base that Q2 FY2027 will be measured against. Take out the extra week and Q1 revenue was about $9,186 million, roughly +7.1% against $8,578 million (my arithmetic, applying the company’s $570 million estimate to reported revenue).
Revenue by segment
| Segment (reported revenue vs same quarter a year earlier) | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|
| Cardiovascular | $3,436 million vs $3,102 million, +10.8% | $3,457 million vs $3,037 million, +13.8% | $3,797 million vs $3,336 million, +13.8% | $3,927 million vs $3,285 million, +19.5% |
| Neuroscience | $2,562 million vs $2,451 million, +4.5% | $2,558 million vs $2,458 million, +4.1% | $2,751 million vs $2,620 million, +5.0% | $2,678 million vs $2,427 million, +10.3% |
| Medical Surgical | $2,171 million vs $2,128 million, +2.0% | $2,173 million vs $2,072 million, +4.9% | $2,388 million vs $2,212 million, +8.0% | $2,279 million vs $2,073 million, +9.9% |
| Diabetes | $757 million vs $686 million, +10.3% | $796 million vs $694 million, +14.7% | $837 million vs $728 million, +15.0% | $843 million vs $721 million, +16.9% |
Sources: the same four releases. In Q1 FY2027 the company reported organic growth of 18.9% in Cardiovascular, 9.3% in Neuroscience, 10.2% in Medical Surgical and 14.9% in Diabetes, with Cardiac Ablation Solutions up 88%. Every segment figure above includes the extra week in Q1, so the Q1 column overstates the underlying pace.
The FY2027 guidance, and what it implies for the rest of the year
| Guidance | June 3, 2026 (initial) | September 1, 2026 (raised) |
|---|---|---|
| FY2027 organic revenue growth | 6.75% to 7.25% | 7.25% to 7.75% |
| FY2027 non-GAAP diluted EPS | $5.90 to $6.00 | $5.94 to $6.00 |
| Q2 FY2027 (given on the September 1 call) | not given in the release | about 6% organic revenue growth; non-GAAP EPS of $1.32 to $1.34; currency headwind of $25 million to $75 million |
Sources: the June 3 and September 1 releases; the Q2 figures are from the transcript of the September 1 call (Equibles), not the release. The company says the raised full-year guidance includes the extra selling week (first quarter presentation). The release gives no reported-revenue guidance; the presentation shows implied FY2027 adjusted revenue of about $38.9 billion to $39.2 billion, which I use below as approximate.
| Step (my calculation) | Non-GAAP diluted EPS | Revenue |
|---|---|---|
| FY2027 guidance | $5.94 to $6.00 | about $38.9 billion to $39.2 billion |
| Less Q1 FY2027 actual | $1.45 | $9,756 million |
| Implied Q2 to Q4 FY2027 | $4.49 to $4.55 | about $29.1 billion to $29.4 billion |
| Q2 to Q4 FY2026 actual | $4.27 ($1.36 + $1.36 + $1.55) | $27,785 million ($8,961 + $9,017 + $9,807 million) |
| Implied growth, Q2 to Q4 FY2027 vs Q2 to Q4 FY2026 | +5.2% to +6.6% | +4.9% to +6.0% |
| Q2 FY2027 guidance vs $1.36 a year earlier | $1.32 to $1.34, -2.9% to -1.5% | about 6% organic |
The arithmetic says the guidance does not need a speed-up in revenue: +4.9% to +6.0% for the last three quarters is close to the roughly 6% the company guided for Q2 and to the +5.7% consensus below. EPS is different. Q2 is guided down 1.5% to 2.9%, so the rest of the year has to carry the growth: with $1.32 to $1.34 for Q2, the implied second half (Q3 plus Q4) is $3.15 to $3.23 against $2.91 a year earlier (Q3 $1.36 plus Q4 $1.55), or +8.2% to +11.0% (my arithmetic, using the widest pairing of the ranges; rounding in the guided figures widens it slightly). It is arithmetic, not a company forecast, and the revenue range rests on a presentation figure that the company rounded.
What analysts expect, and the share price
This section uses third-party data, which is not from the company; each figure carries its source. Consensus is for the same quarter, compared with the same quarter a year earlier.
| Q2 FY2027 metric | Consensus | Q2 FY2026 actual (company) | Change |
|---|---|---|---|
| Non-GAAP diluted EPS | $1.34 (Earnings Whispers) | $1.36 | -1.5% |
| Unofficial whisper number (not a consensus) | $1.37 (Earnings Whispers) | $1.36 | +0.7% |
| Revenue | $9.47 billion (Earnings Whispers) | $8.961 billion | +5.7% |
The Earnings Whispers preview is dated November 16, 2026; I found no second consensus source for this quarter to compare it with, so treat the numbers as one provider’s view. The consensus EPS of $1.34 sits at the top of the company’s own Q2 range of $1.32 to $1.34. For the full year the same preview puts consensus EPS at $5.94, the bottom of the $5.94 to $6.00 range, and revenue at $38.64 billion, below the roughly $39.0 billion the guidance implies.
MDT closed at $100.71 on Wednesday, November 18, 2026 (source: YCharts). Earnings Whispers quoted $102.86 in the text of its November 16 preview. StockAnalysis.com, in a page last checked November 7, 2026, showed an average analyst rating of Buy from 30 analysts and a 12-month price target of $104.62. Against the figures above (my calculation):
| Measure | Value |
|---|---|
| Share price (NYSE close, Nov 18, 2026) | $100.71 |
| Price to FY2026 non-GAAP EPS of $5.53 | 18.2x |
| Price to the FY2027 non-GAAP EPS guidance midpoint of $5.97 | 16.9x |
| Quarterly dividend of $0.72, $2.88 a year | yield 2.86% on the price above |
| Annual dividend as a share of FY2026 non-GAAP EPS ($5.53) | 52.1% |
| Annual dividend as a share of FY2026 GAAP EPS ($3.73) | 77.2% |
Price and consensus move daily, so check both with your broker before the release.
What to watch on November 24
- Organic revenue growth against the roughly 6% guided for Q2, now that the extra week is gone. Q1 without it was about +7.1% on my arithmetic, and the full-year guide is +7.25% to +7.75% including the extra week.
- Non-GAAP EPS against $1.36 a year earlier and the guided $1.32 to $1.34. Consensus is $1.34 and the whisper $1.37, so the market is asking for the top of the range or slightly better.
- Cardiac ablation: sales grew 88% in Q1 (company). Earnings Whispers says management guided to more than three times market growth for Q2, and the call summary from BigGo says growth is expected to moderate as comparisons toughen; both are third-party accounts that I could not check against a transcript line.
- Breadth outside cardiology: Neuroscience grew 9.3% organically in Q1 with Cranial and Spinal Technologies up 13%. Earnings Whispers flags neuromodulation and structural heart as weaker areas to check.
- Margins and tariffs: the call summary from BigGo says the full-year operating margin expansion was trimmed to about 50 basis points from 60, and that Q1 tariff costs were largely offset by refunds with no further refunds assumed in guidance (third-party summary).
- Full-year guidance: whether EPS stays at $5.94 to $6.00 and how organic growth is updated. The EPS range is narrow, so even a one-cent move at either end would be noticed.
- What comes next: Earnings Whispers lists an investor day on December 10 and 11, and the BigGo summary says the planned MiniMed separation is intended to close before fiscal year-end. Both are third-party accounts; check the company’s investor relations page.
The dividend
The quarterly dividend is $0.72 per share, $2.88 a year. On June 3, 2026 the board raised it for the first quarter of fiscal 2027, the 49th consecutive annual increase, and Medtronic is a member of the S&P 500 Dividend Aristocrats index (company releases). The previous quarterly amount was $0.71 (declared December 4, 2025), so the increase was $0.01, or about 1.4% (my calculation). The latest declaration, on August 20, 2026, was $0.72 for the second quarter of fiscal 2027, to shareholders of record on September 25, 2026 and payable on October 16, 2026. That record date has passed, so no ex-dividend date for MDT falls around the results.
Last year the company declared its next dividend on December 4: $0.71, record date December 26, payable January 16, 2026. As of November 19, 2026 I found no announcement of the next dividend, so its amount and dates are unconfirmed; the December timing is only last year’s pattern, not a statement about this year.
For investors in Europe
- MDT trades on the NYSE and pays in dollars. The company is Irish-resident, so Irish dividend withholding tax applies on top of the usual U.S. paperwork: Medtronic’s investor relations page gives the rate as 25% and says the vast majority of shareholders are entitled to an exemption, with the route depending on how you hold the shares. Ask your broker how it handles the exemption, and see our W-8BEN guide and our dividend withholding tax guide.
- The yield is about 2.86% on the price above, and the euro value of both the share price and the dividend moves with the dollar.
Sources
- Medtronic: announcement of the Q2 FY2027 results date, time and webcast (November 4, 2026)
- Medtronic: first quarter fiscal 2027 results, Form 8-K exhibit (September 1, 2026); first quarter earnings presentation
- Medtronic: fourth quarter and full-year fiscal 2026 results, Form 8-K exhibit (June 3, 2026)
- Medtronic: third quarter fiscal 2026 results (February 17, 2026); second quarter fiscal 2026 results (November 18, 2025)
- Dividend declarations: August 20, 2026; December 4, 2025; Medtronic: Irish dividend withholding tax information
- Third-party data (consensus, price, call commentary), not from the company: Earnings Whispers preview (November 16, 2026; viewed November 19, 2026); YCharts (close of November 18, 2026); StockAnalysis.com (page last checked November 7, 2026); Equibles transcript of the September 1, 2026 call; BigGo Finance summary of the September 1, 2026 call
Get new articles by email
Ex-dividend dates, earnings previews and P2P platform changes, straight to your inbox. Unsubscribe anytime.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Company figures are taken from the releases listed; consensus, the share price and call commentary come from the third-party sources listed, as of the dates stated; and the implied-guidance, valuation and payout figures are my own arithmetic, not a company forecast. Confirm current figures with your broker or the company’s investor relations page. Investing involves risk, including the possible loss of capital, and a dividend payment is never guaranteed.
Follow our news in Google
Add My Passive Income as a preferred source, so our articles are more likely to show up in your Top Stories.


